[Radiation sensitivity studies of inoperable and recurrent rectal carcinomas].
Two pilot studies on the radiosensitivity of rectum carcinomas have been conducted, during which 42 patients with inoperable primary tumors or recurrences were irradiated with focal doses of about 60 Gy. A rate of 38% of objective remissions was observed under conventional telecobalt irradiation, 20% were progressing in spite of radiotherapy. In case of simultaneous peroral administration of razoxane, an objective remission rate of 67% was observed, and none of the tumors was progressing during or immediately after radiotherapy. Remissions were found most frequently in inoperable primary tumors and anastomotic recurrences. The radiosensitivity of the recurrent rectum carcinoma has to be considered as only fairly good. Nevertheless, local recurrences without remote metastases should always be treated by radiotherapy, because a much better median survival time and quality of life can be achieved than by a mere symptomatic therapy.
Rhomberg
W
W
Abteilung Radio-Onkologie, Landeskrankenhaus Feldkirch, Osterreich.
Eiter
H
H
D001918:Brachytherapy / Q000009:adverse effects; D002588:Cesium Radioisotopes / Q000627:therapeutic use; D003037:Cobalt Radioisotopes / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000532:radiotherapy*; D010166:Palliative Care / Q000009:adverse effects / Q000379:methods; D011446:Prospective Studies; D011832:Radiation Injuries / Q000453:epidemiology; D011836:Radiation Tolerance; D011838:Radiation-Sensitizing Agents; D011867:Radioisotope Teletherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D011929:Razoxane / Q000009:adverse effects / Q000627:therapeutic use; D012004:Rectal Neoplasms / Q000188:drug therapy / Q000532:radiotherapy*; D012074:Remission Induction
D002588:Cesium Radioisotopes; D003037:Cobalt Radioisotopes; D011838:Radiation-Sensitizing Agents; D011929:Razoxane
Studien zur Strahlensensibilität inoperabler und rezidivierender Rektumkarzinome.